A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2433 views | HTML 2686 views | ?
Xiao-Hua Zhang1, Shuai Hao1, Bo Gao1, Wu-Guo Tian1, Yan Jiang1, Shu Zhang1, Ling-Ji Guo1, Dong-Lin Luo1
1Department of Breast, Thyroid Surgery, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China
Dong-lin Luo, email: [email protected]
Keywords: metastatic/advanced breast cancer, chemotherapy, toxicity, randomized controlled trials, bayesian network model
Received: June 08, 2016 Accepted: October 17, 2016 Published: November 02, 2016
Objective: To compare the incidence of toxicity of 8 different chemotherapy regimens, including doxorubicin + paclitaxel, doxorubicin, capecitabine, CMF (cyclophosphamide + methotrexate + 5-fluorouracil), FAC (fluorouracil + doxorubicin + cyclophosphamide), doxorubicin + docetaxel, doxorubicin + cyclophosphamide and paclitaxel in the treatment of metastatic/advanced breast cancer.
Results: This network meta-analysis included 8 randomized controlled trials (RCTs). The findings revealed that, with regard to capecitabine alone regimen exhibited higher incidence of nausea/vomiting than doxorubicin + paclitaxel regimen, doxorubicin alone regimen and paclitaxel alone regimen in the treatment of patients with metastatic/advanced breast cancer (OR = 32.48, 95% CI = 1.65~2340.57; OR = 22.75, 95% CI = 1.03~1923.52; OR = 59.63, 95% CI = 2.22~5664.88, respectively). Furthermore, doxorubicin + cyclophosphamide regimen had lower incidence of febrile neutropenia than doxorubicin + docetaxel (OR = 0.17, 95% CI = 0.03~0.96). No significant difference in the incidence of stomatitis was observed among eight chemotherapy regimens.
Materials and methods: We initially searched PubMed, Cochrane Library and Embase databases from the founding of these databases to January 2016. Eligible studies investigating the 8 different chemotherapy regimens for treatment of metastatic/advanced breast cancer were included for direct and indirect comparison. The odds ratio (OR) and surface under the cumulative ranking curves (SUCRA) value of the incidence of toxicity among eight chemotherapy regimens were analyzed.
Conclusions: Capecitabine alone regimen and doxorubicin + docetaxel regimen may have a more frequent toxicity in the treatment of metastatic/advanced breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.